Benzinga | Mar 25, 2021 06:18AM EDT

Piper Sandler Initiates Coverage On Pulmonx with Neutral Rating, Announces Price Target of $50

Piper Sandler analyst Jason Bednar initiates coverage on Pulmonx (NASDAQ:LUNG) with a Neutral rating and announces Price Target of $50.